Biobanking, bioprocessing and analytics leader IBX has acquired UK-based biospecimen storage specialists Roylance Pharma, according to a press release.
Marieanne Miller, co-founder of Roylance Pharma said, "We’re excited to bring the Roylance Pharma teams expertise into IBX. With decades of combined experience in MHRA licensed stability storage, bio-storage, on-site servicing and photo stability testing behind us this acquisition will enable us to offer our clients the same high level of attention across a wider range of services."
IBX previously operated as RUCDR Infinite Biologics before spinning off from Rutgers University-New Brunswick in August, according to a press release.
Benedict Roylance, co-founder of Roylance Pharma, said in a press release, "Joining Roylance Pharma and IBX is a natural fit that will benefit both groups of clients and teams. Expanding our reach internationally and sharing the wealth of expertise within both businesses means we can drive further growth and offer greater support in our clients’ research projects."
IBX touts itself as a market-disrupting next-generation central laboratory proving services in the areas of academia, government, and industry, according to a press release.
"We are excited to welcome the Roylance Pharma team into the IBX family," said Robin Grimwood, Infinity BiologiX CEO. "Combining our two great organizations serves to strengthen the support we provide our clients whilst accelerating our already impressive growth on an international scale."